16
Jul

Boehringer Ingelheim’s treatment for a rare and deadly lung disease picked up the FDA’s coveted breakthrough therapy designation, a mark that guarantees a speedy regulatory review and could help the company beat its nearest rival to market.

…read more

Source: Boehringer’s lung drug wins FDA ‘breakthrough’ tag

    

0 No comments